Endocrine Abstracts

Objective: Head-to-head data comparing selpercatinib, a highly selective and potent RE arranged during Transfection (RET) kinase inhibitor with CNS activity, to standard treatment of RET-altered medullary thyroid cancer (MTC; cabozantinib or vandetanib) is currently unavailable. This post-hoc comparative effectiveness analysis of data from the phase 1/2 LIBRETTO-001 trial compared investigator-assessed outcomes among patients with RET</e...